-
1.发明授权Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers 有权用于鉴定，分类和监测具有Bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物公开(公告)号：US09045800B2
公开(公告)日：2015-06-02
申请号：US12704165
申请日：2010-02-11
申请人： Dimitri Semizarov , Tamar Uziel , David Ching Siang Huang , Mark F. van Delft , Christin Tse , Richard R. Lesniewski
发明人： Dimitri Semizarov , Tamar Uziel , David Ching Siang Huang , Mark F. van Delft , Christin Tse , Richard R. Lesniewski
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/57496 , G01N2333/4703
摘要： The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-xL and in cancer or tumor cells, or elevated Bcl-xL polypeptide expression.
摘要翻译： 本发明涉及允许鉴定，分类和监测癌症患者Bcl-2家族抑制剂疗法的方法和试剂盒。 本发明的方法和组合物涉及确定Bcl-xL和癌症或肿瘤细胞中的扩增或升高的Bcl-xL多肽表达。
-
2.发明申请METHODS AND COMPOSITIONS FOR IDENTIFYING, CLASSIFYING AND MONITORING SUBJECT HAVING BCL-2 FAMILY INHIBITOR-RESISTANT TUMORS AND CANCERS 有权用于鉴定，分类和监测具有BCL-2家族阻抑性肿瘤和癌症的受试者的方法和组合物公开(公告)号：US20100234239A1
公开(公告)日：2010-09-16
申请号：US12704165
申请日：2010-02-11
申请人： Dimitri Semizarov , Tamar Uziel , David Ching Siang Huang , Mark F. van Delft , Christin Tse , Richard R. Lesniewski
发明人： Dimitri Semizarov , Tamar Uziel , David Ching Siang Huang , Mark F. van Delft , Christin Tse , Richard R. Lesniewski
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/57496 , G01N2333/4703
摘要： The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-xL and in cancer or tumor cells, or elevated Bcl-xL polypeptide expression.
摘要翻译： 本发明涉及允许鉴定，分类和监测癌症患者Bcl-2家族抑制剂疗法的方法和试剂盒。 本发明的方法和组合物涉及确定Bcl-xL和癌症或肿瘤细胞中的扩增或升高的Bcl-xL多肽表达。
-
公开(公告)号：US20100184026A1
公开(公告)日：2010-07-22
申请号：US12357588
申请日：2009-01-22
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57484 , G01N2333/52 , G01N2800/52
摘要： Methods for identifying cancer patients eligible to receive endothelin receptor antagonist therapy and for monitoring patient response to endothelin receptor antagonist therapy comprise assessment of the expression levels of at least one of PAI-1, uPA, TGFbeta2, IL-6, IL-8 and OPG in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive endothelin receptor antagonist therapy and of determination of patient response to the therapy.
摘要翻译： 鉴定符合接受内皮素受体拮抗剂治疗和监测患者对内皮素受体拮抗剂治疗反应的癌症患者的方法包括评价PAI-1，uPA，TGFβ2，IL-6，IL-8和OPG中的至少一种的表达水平 在患者组织样本中。 本发明的方法允许更有效地鉴定患者以接受内皮素受体拮抗剂治疗和确定患者对治疗的反应。
-
公开(公告)号：US20080102451A1
公开(公告)日：2008-05-01
申请号：US11590007
申请日：2006-10-31
IPC分类号： G01N33/50 , C12Q1/68 , G01N33/52 , G01N33/53 , G01N33/543
CPC分类号： G01N33/57434 , C12Q1/6886 , C12Q2600/106 , G01N33/57407 , G01N2333/495 , G01N2333/5412 , G01N2333/8121 , G01N2333/9723 , Y10T436/24
摘要： Methods for identifying cancer patients eligible to receive endothelin receptor antagonist therapy and for monitoring patient response to endothelin receptor antagonist therapy comprise assessment of the expression levels of at least one of PAI-1, uPA, TGFbeta2, IL-6, IL-8 and OPG in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive endothelin receptor antagonist therapy and of determination of patient response to the therapy.
摘要翻译： 鉴定符合接受内皮素受体拮抗剂治疗和监测患者对内皮素受体拮抗剂治疗反应的癌症患者的方法包括评价PAI-1，uPA，TGFβ2，IL-6，IL-8和OPG中的至少一种的表达水平 在患者组织样本中。 本发明的方法允许更有效地鉴定患者以接受内皮素受体拮抗剂治疗和确定患者对治疗的反应。
-
5.发明授权Hepatitis C virus second envelope (HCV-E2) glycoprotein expression system 失效丙型肝炎病毒第二包膜（HCV-E2）糖蛋白表达系统
公开(公告)号：US6020122A
公开(公告)日：2000-02-01
申请号：US478073
申请日：1995-06-07
IPC分类号： A61K39/12 , A61P31/04 , C07K14/18 , G01N33/543 , G01N33/569 , G01N33/576 , C12Q1/70
CPC分类号： C07K14/005 , G01N33/56988 , G01N33/5767 , A61K39/00 , C12N2770/24222
摘要： This invention provides a novel mammalian expression system that is capable of generating high levels of expressed hepatitis C virus (HCV) proteins which have previously proved difficult to express due to their non-secretory properties. In particular, the invention provides a plasmid for the expression of the HCV second envelope protein (E2) designated p577. This plasmid encodes a recombinant protein comprising the immunoglobulin signal peptide and amino acids 388-664 of the HCV E2 glycoprotein. This unique expression system produces high levels of HCV proteins that are properly processed, glycosylated, and folded.
摘要翻译： 本发明提供了一种能够产生高水平的丙型肝炎病毒（HCV）蛋白质的新型哺乳动物表达系统，其先前被证明由于其非分泌性质而难以表达。 特别地，本发明提供了用于表达指定为p577的HCV第二包膜蛋白（E2）的质粒。 该质粒编码包含HCV E2糖蛋白的免疫球蛋白信号肽和氨基酸388-664的重组蛋白。 这种独特的表达系统产生高水平的HCV蛋白，其被适当加工，糖基化和折叠。
-
公开(公告)号：US06596476B1
公开(公告)日：2003-07-22
申请号：US08905054
申请日：1997-08-01
IPC分类号： C12Q170
CPC分类号： C07K14/005 , C12N2770/24222 , G01N33/5767 , Y10S436/82
摘要： The present invention provides an improved assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with at least one polypeptide containing at least one epitope of an HCV antigen. Preferred assay formats include a confirmatory assay, a combination assay, a synthetic polypeptide-based assay, an immunodot assay and a competition assay.
摘要翻译： 本发明提供了一种用于通过使样品与至少一种含有HCV抗原的至少一个表位的多肽接触来检测样品中HCV抗原的抗体的改进的测定法。 优选的测定形式包括确认测定，组合测定，基于合成多肽的测定，免疫斑点测定和竞争测定。
-
公开(公告)号：US08748108B2
公开(公告)日：2014-06-10
申请号：US13311752
申请日：2011-12-06
CPC分类号： G01N33/574 , G01N33/57484
摘要： Disclosed are methods for classifying a patient with cancer as a candidate for therapy with a Bcl-2 family inhibitor comprising determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level. Also described are methods for identifying classes of patients having a refractory cancer for second-line therapy comprising a Bcl-2 family inhibitor, where the method comprises determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level.
摘要翻译： 公开了用于将患有癌症的患者分类为用Bcl-2家族抑制剂治疗的候选物的方法，包括确定样品中至少一种生物标志物的水平并将生物标志物水平与阈值水平进行比较。 还描述了用于鉴定包含Bcl-2家族抑制剂的用于二线治疗的难治性癌症的患者类别的方法，其中所述方法包括测定样品中至少一种生物标志物的水平并将生物标志物水平与阈值水平进行比较 。
-
公开(公告)号：US06593083B1
公开(公告)日：2003-07-15
申请号：US09690359
申请日：2000-10-17
申请人： Sushil G. Devare , Suresh M. Desai , James M. Casey , Stephen H. Dailey , George J. Dawson , Robin A. Gutierrez , Richard R. Lesniewski , James L. Stewart , Kevin R. Rupprecht
发明人： Sushil G. Devare , Suresh M. Desai , James M. Casey , Stephen H. Dailey , George J. Dawson , Robin A. Gutierrez , Richard R. Lesniewski , James L. Stewart , Kevin R. Rupprecht
IPC分类号： C12Q170
CPC分类号： C07K14/005 , A61K39/00 , C07K2319/00 , C12N9/1241 , C12N2770/24222
摘要： Unique recombinant antigens representing distinct antigenic regions of the Hepatitis C Virus (HCV) genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to HCV. The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigens. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.
摘要翻译： 代表丙型肝炎病毒（HCV）基因组的不同抗原区域的独特重组抗原，其可以用作检测暴露于HCV的个体的体液中抗体和抗原的试剂。 本发明还提供了通过使样品与重组抗原接触来检测样品中HCV抗原的存在的测定。 优选的测定形式包括筛选测定，确认测定，竞争或中和测定和免疫斑点测定。
-
公开(公告)号：US06172189B2
公开(公告)日：2001-01-09
申请号：US08867611
申请日：1997-06-02
申请人： Sushil G. Devare , Suresh M. Desai , James M. Casey , Stephen H. Dailey , George J. Dawson , Robin A. Gutierrez , Richard R. Lesniewski , James L. Stewart , Kevin R. Rupprecht
发明人： Sushil G. Devare , Suresh M. Desai , James M. Casey , Stephen H. Dailey , George J. Dawson , Robin A. Gutierrez , Richard R. Lesniewski , James L. Stewart , Kevin R. Rupprecht
IPC分类号： A61K3804
CPC分类号： C07K14/005 , A61K39/00 , C07K2319/00 , C12N9/1241 , C12N2770/24222
摘要： The present invention provides unique recombinant antigens representing distinct antigenic regions of the Hepatitis C Virus (HCV) genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to HCV. The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigens. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.
摘要翻译： 本发明提供了代表丙型肝炎病毒（HCV）基因组的不同抗原性区域的独特的重组抗原，其可用作检测来自暴露于HCV的个体的体液中抗体和抗原的试剂。 本发明还提供了通过使样品与重组抗原接触来检测样品中HCV抗原的存在的测定。 优选的测定形式包括筛选测定，确认测定，竞争或中和测定和免疫斑点测定。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.045 秒)
